Communications Biology (Jun 2021)
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
- Pottayil G. Sasikumar,
- Naremaddepalli S. Sudarshan,
- Srinivas Adurthi,
- Raghuveer K. Ramachandra,
- Dodderi S. Samiulla,
- Anirudha Lakshminarasimhan,
- Anuradha Ramanathan,
- Talapaneni Chandrasekhar,
- Amit A. Dhudashiya,
- Sumalatha R. Talapati,
- Nagesh Gowda,
- Sreenivasulareddy Palakolanu,
- Jiju Mani,
- Bandi Srinivasrao,
- David Joseph,
- Nigam Kumar,
- Rashmi Nair,
- Hanudatta S. Atreya,
- Nagaraj Gowda,
- Murali Ramachandra
Affiliations
- Pottayil G. Sasikumar
- Aurigene Discovery Technologies Limited
- Naremaddepalli S. Sudarshan
- Aurigene Discovery Technologies Limited
- Srinivas Adurthi
- Aurigene Discovery Technologies Limited
- Raghuveer K. Ramachandra
- Aurigene Discovery Technologies Limited
- Dodderi S. Samiulla
- Aurigene Discovery Technologies Limited
- Anirudha Lakshminarasimhan
- Aurigene Discovery Technologies Limited
- Anuradha Ramanathan
- Aurigene Discovery Technologies Limited
- Talapaneni Chandrasekhar
- Aurigene Discovery Technologies Limited
- Amit A. Dhudashiya
- Aurigene Discovery Technologies Limited
- Sumalatha R. Talapati
- Aurigene Discovery Technologies Limited
- Nagesh Gowda
- Aurigene Discovery Technologies Limited
- Sreenivasulareddy Palakolanu
- Aurigene Discovery Technologies Limited
- Jiju Mani
- Aurigene Discovery Technologies Limited
- Bandi Srinivasrao
- Aurigene Discovery Technologies Limited
- David Joseph
- NMR Research Centre, Indian Institute of Science
- Nigam Kumar
- Aurigene Discovery Technologies Limited
- Rashmi Nair
- Aurigene Discovery Technologies Limited
- Hanudatta S. Atreya
- NMR Research Centre, Indian Institute of Science
- Nagaraj Gowda
- Aurigene Discovery Technologies Limited
- Murali Ramachandra
- Aurigene Discovery Technologies Limited
- DOI
- https://doi.org/10.1038/s42003-021-02191-1
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 12
Abstract
Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug.
